Literature DB >> 26240948

Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: Role of activity at NMDA receptor.

Kinga Sałat1, Agata Siwek1, Gabriela Starowicz1, Tadeusz Librowski1, Gabriel Nowak2, Urszula Drabik3, Ryszard Gajdosz3, Piotr Popik4.   

Abstract

Ketamine produces rapid and long-lasting antidepressant effects in patients. The involvement of ketamine metabolites in these actions has been proposed. The effects of ketamine and its metabolites norketamine and dehydronorketamine on ligand binding to 80 receptors, ion channels and transporters was investigated at a single concentration of 10 μM. The affinities of all three compounds were then assessed at NMDA receptors using [3H]MK-801 binding. The dose-response relationships of all 3 compounds in the forced swim test were also investigated in mice 30 min after IP administration. The effects of ketamine and norketamine (both 50 mg/kg) were then examined at 30 min, 3 days and 7 days post administration. Among the 80 potential targets examined, only NMDA receptors were affected with a magnitude of >50% by ketamine and norketamine at the concentration of 10 μM. The Ki values of ketamine, norketamine and dehydronorketamine at NMDA receptors were 0.119±0.01, 0.97±0.1 and 3.21±0.3 μM, respectively. Ketamine and norketamine reduced immobility with minimum effective doses (MEDs) of 10 and 50 mg/kg, respectively; dehydronorketamine did not affect immobility at doses of up to 50 mg/kg. Neither ketamine nor norketamine reduced immobility in the forced swim test 3 and 7 days following administration. Further, oral administration of ketamine (5-50 mg/kg) did not affect immobility. We demonstrate that ketamine and norketamine but not dehydronorketamine given acutely at subanesthetic doses reduced immobility in the forced swim test. These antidepressant-like effects appear attributable to NMDA receptor inhibition.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antidepressant-like effects; Dehydronorketamine; Ketamine; Ketamine metabolites; NMDA receptor; Norketamine

Mesh:

Substances:

Year:  2015        PMID: 26240948     DOI: 10.1016/j.neuropharm.2015.07.037

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  20 in total

1.  Ketamine: NMDA Receptors and Beyond.

Authors:  Charles F Zorumski; Yukitoshi Izumi; Steven Mennerick
Journal:  J Neurosci       Date:  2016-11-02       Impact factor: 6.167

2.  Ketamine induces immediate and delayed alterations of OCD-like behavior.

Authors:  Summer L Thompson; Amanda C Welch; Julia Iourinets; Stephanie C Dulawa
Journal:  Psychopharmacology (Berl)       Date:  2020-01-11       Impact factor: 4.530

Review 3.  Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.

Authors:  Carolina Medeiros da Frota Ribeiro; Patricio Riva-Posse
Journal:  Curr Psychiatry Rep       Date:  2017-11-15       Impact factor: 5.285

Review 4.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Lace M Riggs; Jaclyn N Highland; Polymnia Georgiou; Edna F R Pereira; Edson X Albuquerque; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 5.  Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.

Authors:  Weili Zhu; Zengbo Ding; Yinan Zhang; Jie Shi; Kenji Hashimoto; Lin Lu
Journal:  Neurosci Bull       Date:  2016-11-22       Impact factor: 5.203

6.  Morus nigra and its major phenolic, syringic acid, have antidepressant-like and neuroprotective effects in mice.

Authors:  Ana Paula Dalmagro; Anderson Camargo; Ana Lúcia Bertarello Zeni
Journal:  Metab Brain Dis       Date:  2017-08-18       Impact factor: 3.584

7.  Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.

Authors:  Kristian Gaarn du Jardin; Nico Liebenberg; Heidi Kaastrup Müller; Betina Elfving; Connie Sanchez; Gregers Wegener
Journal:  Psychopharmacology (Berl)       Date:  2016-05-28       Impact factor: 4.530

8.  Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.

Authors:  Nolan R Williams; Boris D Heifets; Christine Blasey; Keith Sudheimer; Jaspreet Pannu; Heather Pankow; Jessica Hawkins; Justin Birnbaum; David M Lyons; Carolyn I Rodriguez; Alan F Schatzberg
Journal:  Am J Psychiatry       Date:  2018-08-29       Impact factor: 18.112

9.  Ketamine Inhibition of the Pentameric Ligand-Gated Ion Channel GLIC.

Authors:  Bogdan F Ion; Marta M Wells; Qiang Chen; Yan Xu; Pei Tang
Journal:  Biophys J       Date:  2017-08-08       Impact factor: 4.033

Review 10.  Advances in novel molecular targets for antidepressants.

Authors:  Qingzhong Wang; Yogesh Dwivedi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-07-16       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.